Navigation Links
Advanced Cell Diagnostics Initiates Agreement to Study Biomarkers for Cancer Immunotherapy
Date:3/4/2013

HAYWARD, Calif., March 4th, 2013 /PRNewswire/ -- Advanced Cell Diagnostics, Inc. (ACD) announced today that they have entered into an agreement with The Johns Hopkins University on behalf of its Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins to use ACD's proprietary RNAscope® technology platform to validate novel biomarkers and drug targets for cancer immunotherapy.

Cancer immunotherapy, which aims to mobilize a patient's immune system to fight cancer, has been gaining momentum recently with the FDA approval of anti-CTLA-4 therapy for melanoma and with the recent impressive and durable remissions produced by targeting PD1 in multiple solid tumors in early-phase clinical trials led by Johns Hopkins investigators. With many additional immune modulatory molecules identified for targeting that play major roles in specific subsets of cancer, it will be critical to develop standardized biomarkers to guide the application of the most effective immune therapies on a patient by patient basis.

Targeting the immune checkpoints that are often suppressed in many cancers has demonstrated tremendous potential.  However, to identify biomarkers useful for guiding therapy, conventional approaches to biomarker analysis have proven inadequate, leading to conflicting results.

"The complex interplay between cancer cells and the immune system in the tumor microenvironment matches perfectly with RNAscope's capability of single molecule sensitivity and single cell resolution, which can help pinpoint which cell is talking to which other cell," said Dr. Yuling Luo , Founder, President and CEO of ACD.  Dr. Luo added, "That knowledge will be essential for selecting optimal targets for drug development and predicting which patient will benefit from it. We feel extremely fortunate to be able to provide such a tool to the pioneers in this emerging and exciting field."

About RNAscope
RNAscope technology is the first automated multiplex RNA in situ hybridization platform capable of detecting and quantifying biomarkers with single‐molecule sensitivity. Traditionally, RNA biomarkers are analyzed by "grind‐and‐bind" assays such as RT‐PCR in homogenized tissue, which loses information about cellular context and disease microenvironment that is critical for clinical interpretation. RNAscope provides single‐cell gene expression information within the context of intact tissue, enabling both molecular and histopathological analysis on a platform that is compatible with routine clinical specimens and standard clinical laboratory workflow. Unlike IHC antibodies which are available for only a small fraction of the human proteome and not suitable for the emerging class of non‐coding RNAs, RNAscope assays can be developed and validated in two weeks for virtually any gene in any genome. Currently, ACD offers RNAscope‐based products and services worldwide to scientists in a broad range of research areas from basic research to companion diagnostics for personalized medicine. Customers include world‐renowned academic institutions and all major pharmaceutical/biotech companies.

About Advanced Cell Diagnostics
Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell and tissue‐based diagnostic tests for personalized medicine. The company's products and services are based on its proprietary RNAscope® technology, the first automated multiplex chromogenic and fluorescent in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single‐molecule sensitivity. RNAscope assays are currently used by hundreds of customers, including all of the global top 10 pharmaceutical companies, world leading academic institutions and many cutting edge biotechnology companies to validate biomarkers for the management of cancer and other diseases.  ACD's industrial partnerships provide the foundation for ACD to develop companion diagnostic tests in conjunction with partners' targeted therapeutics. ACD also pursues internal programs to develop and commercialize proprietary diagnostic tests in cancer management. Learn more about ACD and RNAscope technology at www.acdbio.com.

Contact:
Steve Chen , Ph.D.
Chief Operating Officer
(510) 259-9802
schen@acdbio.com


'/>"/>
SOURCE Advanced Cell Diagnostics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Industry Thought Leader to Present Transformational Opportunities for Industry Adoption of Advanced Analytics at 2013 HIMSS Annual Conference & Exhibition
2. SPIE Advanced Lithography will Bring Industry Focus to Next-generation Tools and Systems
3. Rigaku publishes new WDXRF Application: Determination of Metals in Copper Concentrate by Advanced Correction Method for Fused Beads
4. Advanced Cell Diagnostics Appoints Evangeline Gonzalez as Chief Commercial Officer
5. New Advanced High End Brix Refractometer
6. INRS acquires a groundbreaking advanced imaging infrastructure
7. GIN Introduces Advanced Robotics and Dispensing Technnology at SLAS 2013 in Orlando, FL
8. Nanonex Delivered Advanced Nanoimprint Tool NX-B200 to Swinburne University of Technology, Australia
9. University of Pennsylvania Purchases Nanonex Advanced Nanoimprint Tool NX-2600 BA
10. Advanced Polymer Trading to Exhibit at ArabPlast 2013 in Dubai
11. Dallas-Fort Worth Fertility Associates Celebrates First Birth in North Texas from Advanced Trophectoderm Biopsy Screening Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... -- Despite the volatility that continues to envelop ... pre-market research on ActiveWallSt.com directs the investor community,s focus on ... RDUS ), Cerus Corp. (NASDAQ: CERS ), Arrowhead ... Therapeutics Inc. (NASDAQ: FPRX ). Register with us ... http://www.activewallst.com/ On Wednesday, shares in ...
(Date:5/26/2016)... ... May 26, 2016 , ... FireflySci has been ... leading laboratories all over the globe. Their cute firefly logo has been spreading ... cuvettes, FireflySci makes spectrophotometer calibration standards that never require recalibration. These revolutionary ...
(Date:5/25/2016)... , ... May 25, 2016 , ... ... a variety of fracture-specific plating options designed to address fractures of the distal ... fixation solutions. , The Acumed Ankle Plating System 3 is composed of seven ...
(Date:5/25/2016)... ... , ... Scientists at the University of Athens say they have evidence that ... the research that could lead to one good one. Surviving Mesothelioma has just posted ... , The team evaluated 98 mesothelioma patients who got a second kind ...
Breaking Biology Technology:
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):